Retrieve available abstracts of 11 articles: HTML format
Single Articles
March 2025
CHAMBERS LM, Eskander RN, O'Malley DM Targeting the future: Antibody-Drug Conjugates (ADCs) in platinum-sensitive
ovarian cancer in the post-PARP era.
Ann Oncol. 2025;36:244-246. PubMed
November 2024
SECORD AA, Lewin SN, Murphy CG, Cecere SC, et al The Efficacy and Safety of Mirvetuximab Soravtansine in FRalpha-Positive, Third-Line
and Later, Recurrent Platinum-Sensitive Ovarian Cancer: The Single-Arm Phase 2
PICCOLO Trial.
Ann Oncol. 2024 Nov 29:S0923-7534(24)04948-2. doi: 10.1016/j.annonc.2024. PubMedAbstract available
HARTER P, Marth C, Mouret-Reynier MA, Cropet C, et al Efficacy of subsequent therapies in patients with advanced ovarian cancer who
relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25
trial.
Ann Oncol. 2024 Nov 9:S0923-7534(24)04907-X. doi: 10.1016/j.annonc.2024. PubMedAbstract available
September 2024
MONK BJ, Barretina-Ginesta MP, Pothuri B, Vergote I, et al Niraparib first-line maintenance therapy in patients with newly diagnosed
advanced ovarian cancer: final overall survival results from the
PRIMA/ENGOT-OV26/GOG-3012 trial.
Ann Oncol. 2024 Sep 14:S0923-7534(24)03762-1. doi: 10.1016/j.annonc.2024.08.2241 PubMedAbstract available
January 2024
LEDERMANN JA, Matias-Guiu X, Amant F, Concin N, et al ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology
and molecular biology and early, advanced and recurrent disease.
Ann Oncol. 2024 Jan 29:S0923-7534(23)05103-7. doi: 10.1016/j.annonc.2023. PubMedAbstract available
December 2023
MCNEISH IA, Monk BJ Is more of a good thing still a good thing? PARP inhibitor retreatment in
high-grade ovarian carcinoma.
Ann Oncol. 2023;34:1074-1076. PubMed
October 2023
SESSA C, Paluch-Shimon S Reply to the Letter to the Editor 'There is no place for ovarian cancer screening
in hereditary breast-ovarian cancer syndromes (in regard to "ESMO Clinical
Practice Guideline on risk reduction and screening of cancer in hereditary
breast-ovarian canc
Ann Oncol. 2023 Oct 26:S0923-7534(23)04325-9. doi: 10.1016/j.annonc.2023. PubMed
TJALMA WAA There is no place for ovarian cancer screening in hereditary breast-ovarian
cancer syndromes.
Ann Oncol. 2023 Oct 20:S0923-7534(23)04324-7. doi: 10.1016/j.annonc.2023. PubMed
PUJADE-LAURAINE E, Selle F, Scambia G, Asselain B, et al Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed
ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a
phase IIIb trial.
Ann Oncol. 2023 Oct 3:S0923-7534(23)04007-3. doi: 10.1016/j.annonc.2023.09.3110. PubMedAbstract available
August 2023
GONZALEZ-MARTIN A, Harter P, Leary A, Lorusso D, et al Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice
Guideline for diagnosis, treatment and follow-up.
Ann Oncol. 2023 Aug 10:S0923-7534(23)00797-4. doi: 10.1016/j.annonc.2023. PubMed
May 2023
RAY-COQUARD I, Leary A, Pignata S, Cropet C, et al Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall
survival results from the PAOLA-1/ENGOT-ov25 trial.
Ann Oncol. 2023 May 19:S0923-7534(23)00686-5. doi: 10.1016/j.annonc.2023. PubMedAbstract available